

CURRICULUM VITAE

Kelly E. Lyons

Address

Department of Neurology
University of Kansas Medical Center
3599 Rainbow Blvd, Mailstop 2012
Kansas City, KS 66160
(913) 588-7159 (tel)
(913) 588-6920 (fax)
email: kelly.lyons@att.net or klyons@kumc.edu

Date of Birth April 14, 1966
Citizenship United States

Education

Ph.D. August, 1993, University of Kansas, Lawrence, Kansas.
Area: Experimental/Cognitive Psychology
Dissertation Title: "Semantic Memory Impairments With Alzheimer's Disease:
Loss of Semantic Information or Inefficient Lexical Access"

M.A. December, 1990, University of Kansas, Lawrence, Kansas.
Area: Experimental/Cognitive Psychology
Thesis Title: "Variability in Aging and Lexical Processing"

B.A. January, 1988, University of Kansas, Lawrence, Kansas. Major: Psychology

Professional Experience

7/11-present Research Professor of Neurology and Director of Research and Education, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, Kansas

5/03-7/11 Research Associate Professor of Neurology and Director of Research and Education Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, Kansas

1/02- 5/03 Voluntary Faculty, Assistant Professor, Department of Neurology University of Kansas Medical Center, Kansas City, Kansas

1/00-5/03 Research Assistant Professor, Department of Neurology, University of Miami Medical Center, Miami, Florida.

1/98-1/00 Assistant Professor, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.

11/95-01/98 Instructor, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.

4/93-11/95 Post-Doctoral Research in Neurodegenerative Disease, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.

- 1991-1993 Graduate Instructor - Introductory Psychology, University of Kansas, Lawrence, Kansas.
 1992-1992 Graduate Research Assistant - Psycholinguistics and Alzheimer's Disease, University of Kansas, Lawrence, Kansas.
 1990-1991 Teaching Assistant - Statistics, Psychology of Sleep and Dreaming, University of Kansas, Lawrence, Kansas.
 Graduate Research Assistant - Psycholinguistic abilities, inter- and intra-individual differences in performance and attention in older adults, University of Kansas, Lawrence, Kansas.
 1989-1990 Teaching Assistant - Statistics, Graduate Statistical Methods (II) University of Kansas, Lawrence, Kansas.
 Graduate Research Assistant - Aging and semantic memory, University of Kansas, Lawrence, Kansas.
 1988-1989 Teaching Assistant - Introductory Psychology, Honors Statistics, University of Kansas, Lawrence, Kansas.

Professional Service

- 2009-present Co-Editor, International Journal of Neuroscience
 2009-2012 Parkinson Study Group, Scientific Review Committee
 2008-present President, International Essential Tremor Foundation
 2008-2012 Movement Disorder Society, Website Editorial Board
 2007-present Movement Disorder Society Journal CME Chair and Editor
 2007-2009 Movement Disorder Society Web Site Committee
 2006-2009 Parkinson Study Group, Credentials Committee
 2006-2007 Movement Disorder Society Journal CME Subcommittee Chair
 2005-present WE MOVE, Education Committee
 2005-2007 American Academy of Neurology Subcommittee on Education for Non-Neurologists
 2002-2010 Steering Committee, PROGENI – Parkinson's Research: The Organized Genetics Initiative – Parkinson Study Group
 2002-2008 First Vice President, International Essential Tremor Foundation
 2002-2009 Movement Disorder Society, Education Committee
 2001-present Secretary/Treasurer, Tremor Research Group
 2000-2003 IRB for the Protection of Human Subjects in Research – University of Miami
 2000-2002 Secretary, International Tremor Foundation
 1997-present Board of Directors, International Tremor Foundation
 1997-present Coordinator, Movement Disorders Review Courses
 1997-1999 Research Board of Directors, John Knox Village
 1996-1999 Editor, *Parkinson's Update*, Parkinson's Association of Greater KC
 1994-present Facilitator, Parkinson's support group (John Knox Village)
 1994-2000 Board of Directors, Parkinson's Association of Greater Kansas City

Affiliations

American Academy of Neurology
 International Essential Tremor Foundation
 Movement Disorder Society
 National Parkinson Foundation

Parkinson Study Group
Tremor Research Group
WE MOVE

Books

1. Hauser RA, **Lyons KE**, Pahwa R, Zesiewicz TA. *Parkinson's Disease Questions and Answers (4th Edition)*. Merit Publishing International: West Palm Beach, Florida, 2003.
2. Pahwa R, **Lyons KE**. *Management of Early Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY, 2009.
3. Pahwa R, **Lyons KE**. *Treatment Decisions in Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY, 2010.
4. Pahwa R, **Lyons KE**. *Early Recognition and Diagnosis in Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY, 2011.
5. Pahwa R, **Lyons KE**. *Recognition and Treatment of Non-Motor Symptoms of Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY, 2011.
6. Pahwa R, **Lyons KE**. *Management of Motor Fluctuations and Dyskinesia in Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY 2012.
7. Pahwa R, **Lyons KE**. *Diagnostic and Treatment Guidelines for Parkinson's Disease, Oxford American Pocket Notes*. Oxford University Press: New York, NY, 2013.

Edited Books

1. Pahwa R, **Lyons KE**, Koller WC. *Handbook of Parkinson's Disease (3rd Edition)*. Marcel Dekker: New York, NY, 2003.
2. Pahwa R, **Lyons KE**, Koller WC. *Therapy of Parkinson's Disease (3rd Edition)*. Marcel Dekker: New York, NY, 2004.
3. **Lyons KE**, Pahwa R. *Handbook of Essential Tremor and Other Tremor Disorders*. Taylor & Francis: Boca Raton, FL, 2005.
4. Pahwa R, **Lyons KE**. *Handbook of Parkinson's Disease (4th Edition)*. Informa Healthcare: New York: 2007.

Peer Reviewed Publications

1. Kemper S, Anagnopoulos C, **Lyons K**, Heberlein W. Speech accommodations to dementia. *J Gerontol* 1994;49:P223-P229.
2. **Lyons KE**, Kemper S, LaBarge E, Ferraro FR, Balota D, Storandt M. Oral language and Alzheimer's disease: a reduction in syntactic complexity. *Aging and Cognition* 1994;1:271-281.
3. Kemper S, **Lyons KE**, Anagnopoulos C. Joint story-telling by Alzheimer's patients and their spouses. *Discourse Processes* 1995;20:205-217.
4. **Lyons KE**, Kellas G, Martin M. Inter- and intra-individual differences in semantic priming among young and older adults. *Exp Aging Res* 1995;21:221-237.
5. Troster AI, Paolo AM, **Lyons KE**, Glatt SL, Hubble JP, Koller WC. The influence of depression on cognition in Parkinson's Disease: A pattern of impairment distinguishable from Alzheimer's Disease *Neurology* 1995;45:672-676.
6. Anouti A, Schmidt K, **Lyons KE**, Hubble JP, Schellenberg G, Golbe LI, Lang AE, Galvez-Jimenez

- N, Hershey L, Koller WC. Normal distribution of Apolipoprotein E alleles in Progressive Supranuclear Palsy. *Neurology* 1996;46:1156-1157.
7. Busenbark K, Barnes P, **Lyons K**, Ince D, Villagra F, Koller WC. Accuracy of reported family history of essential Tremor. *Neurology* 1996;47:264-265.
 8. Glatt SL, Hubble JP, **Lyons K**, Paolo A, Troster AI, Hassanein RES, Koller WC. Risk factors for dementia in Parkinson's disease: effect of education. *Neuroepidemiology* 1996;15:20-25.
 9. Hubble JP, Busenbark KL, Wilkinson S, Penn RD, **Lyons K**, Koller WC. Deep brain stimulation for essential Tremor. *Neurology* 1996;46:1150-1153.
 10. Pahwa R, **Lyons K**, McGuire D, Dubinsky R, Hubble JP, Koller WC. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/ levodopa and sustained-release carbidopa/ levodopa. *Neurology* 1996;46:1059-1062.
 11. Pahwa R, Marjama J, McGuire D, **Lyons K**, Zwiebel F, Silverstein P, Ward R, Koller WC. Pharmacokinetic comparison of sinemet and atamet (Generic Carbidopa/ levodopa): a single dose study. *Mov Disord* 1996;11:427-430.
 12. Burns JM, Wilkinson S, Overman J, Kieltyka J, Lundsgaarde T, Tollefson T, Koller WC, Pahwa R, Troster AI, **Lyons KE**, Batnitzky S, Wetzel L, Gordon MA. Magnetic resonance image evaluation of pallidotomy lesions: a volumetric and shape analysis. *Neurosurg Focus* 1997;2:Article 3.
 13. Burns JM, Wilkinson S, Kieltyka J, Overman J, Lundsgaarde T, Tollefson T, Koller WC, Pahwa R, Troster AI, **Lyons KE**, Batnitzky S, Wetzel L, Gordon MA. Analysis of pallidotomy lesion positions using three-dimensional reconstruction of pallidal lesions, basal ganglia and optic tract. *Neurosurgery* 1997;41:1303-1318.
 14. Hubble JP, Busenbark KL, Pahwa R, **Lyons K**, Koller WC. Clinical expression of essential tremor: effects of gender and age. *Mov Disord* 1997;12:969-972.
 15. Hubble, JP, Busenbark KL, Wilkinson S, Pahwa R, Paulson GW, **Lyons K**, Koller WC. Effects of thalamic deep brain stimulation (DBS) based on tremor type and diagnosis. *Mov Disord* 1997;12:337-341.
 16. **Lyons KE**, Pahwa R, Troster AI, Koller WC. A comparison of Parkinson's disease symptoms and self-reported functioning and well being. *Parkinsonism Relat Disord* 1997;3:207-209.
 17. Miyawaki E, **Lyons K**, Pahwa R, Troster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC. Motor complications of chronic levodopa therapy in Parkinson's disease. *Clin Neuropharmacol* 1997;20:523-530.
 18. Pahwa R, **Lyons K**, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC. Comparison of standard carbidopa/levodopa and sustained-release carbidopa/levodopa in Parkinson's disease: Pharmacokinetic and quality of life measures. *Mov Disord* 1997; 12:677-681.
 19. Pahwa R, Wilkinson S, Smith D, **Lyons K**, Miyawaki E, Koller WC. High frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. *Neurology* 1997;49:249-253.
 20. Small JA, Kemper S, **Lyons K**. Sentence comprehension Alzheimer's disease: effects of grammatical complexity, speech rate, and repetition. *Psychol Aging* 1997;12:3-11.
 21. Small JA, **Lyons K**, Kemper S. Grammatical abilities in Parkinson's disease: evidence from written sentences. *Neuropsychologia* 1997;35:1571-1576.
 22. Troster AI, Fields JA, Wilkinson SB, Pahwa R, Miyawaki E, **Lyons KE**, Koller WC. Unilateral pallidal stimulation for Parkinson's disease: neurobehavioral functioning before and 3 months after electrode implantation. *Neurology* 1997;49:1078-1083.
 23. Ellis RJ, Jan K, Kawas C, Koller WC, **Lyons KE**, Jeste DV, Hansen LA, Thal LJ. Diagnostic validity of the dementia questionnaire for Alzheimer's disease. *Arch Neurol* 1998;55:360-365.
 24. Goodman SH, Wilkinson S, Overman J, Koller WC, Troster A, Pahwa R, **Lyons K**, Kieltyka J, Burns

- J, Gordon M. Lesion volume and clinical outcome in stereotactic pallidotomy and thalamotomy. *Stereotact Funct Neurosurg* 1998;71:164-172.
25. **Lyons KE**, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. *Clin Neuropharmacol* 1998;21:118-121.
 26. **Lyons KE**, Pahwa R, Busenbark KL, Troster AI, Wilkinson S, Koller WC. Improvements in daily functioning after deep brain stimulation of the thalamus for intractable tremor. *Mov Disord* 1998;13:690-692.
 27. Pahwa R, **Lyons K**, Hubble JP, Busenbark K, Rienenrth JD, Pahwa A, Koller WC. Double-blind controlled trial of gabapentin in essential tremor. *Mov Disord* 1998;13:465-467
 28. Tollefson TT, Burns J, Wilkinson S, Overman J, Kieltyka J, Goodman SH, Koller WC, Troster A, **Lyons K**, Pahwa R, Batnitzky S, Wetzel L, Gordon M. Comparative magnetic resonance image-based evaluation of thalamotomy and pallidotomy lesion volumes. *Stereotact Funct Neurosurg* 1998;71:131-144.
 29. Tsao K, Wilkinson S, Overman J, Tollefson T, Koller WC, Pahwa R, Troster AI, **Lyons KE**, Kieltyka J, Batnitzky S, Wetzel L, Gordon MA. Comparison of actual pallidotomy lesion location with expected stereotactic location. *Stereotact Funct Neurosurg* 1998;71:1-19.
 30. Hogan T, Grimaldi R, Dingemans J, Martin M, **Lyons K**, Koller W. The Parkinson's Disease Symptom Inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects. *Parkinsonism Relat Disord* 1999;5:93-98.
 31. Koller WC, **Lyons KE**, Wilkinson SB, Pahwa R. Efficacy of unilateral deep brain stimulation of the VIM nucleus of the thalamus for essential head tremor. *Mov Disord* 1999;14:847-850.
 32. Montgomery EB, Baker KB, **Lyons K**, Koller WC. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. *Neurology* 1999;52:757-762.
 33. Pahwa R, **Lyons KE**, Wilkinson SB, Carpenter MA, Troster AI, Searl JP, Overman J, Pickering S, Koller WC. Bilateral thalamic stimulation for the treatment of essential tremor. *Neurology* 1999;53:1447-1450.
 34. Troster AI, Fields JA, Pahwa R, Wilkinson SB, Straits-Troster KA, **Lyons K**, Kieltyka J, Koller WC. Neuropsychological and quality of life outcome after thalamic stimulation for essential tremor. *Neurology* 1999;53:1774-1780.
 35. Dubinsky RM, Stein AC, **Lyons K**. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000;54:2205-2211.
 36. Hristova A, **Lyons K**, Troster AI, Pahwa R, Wilkinson SB, Koller WC. Effect and time course of deep brain stimulation of the globus pallidus and subthalamus on motor features of Parkinson's disease. *Clin Neuropharmacol* 2000;23:208-11.
 37. Kirschman DL, Milligan B, Wilkinson S, Overman J, Wetzel L, Batnitzky S, **Lyons K**, Pahwa R, Koller WC, Gordon MA. Pallidotomy microelectrode targeting: neurophysiology-based target refinement. *Neurosurgery* 2000;46:613-622.
 38. Milanov I, Kmetski T, **Lyons KE**, Koller WC. Prevalence of Parkinson's disease in Bulgarian gypsies. *Neuroepidemiology* 2000;19:206-209.
 39. Montgomery EB, Baker KB, **Lyons K**, Koller WC. Motor initiation and execution in essential tremor and Parkinson's disease. *Mov Disord* 2000;15:511-515.
 40. Montgomery EB, Koller WC, LaMantia TJK, Newman MC, Swanson-Hyland E, Kaszniak AW, **Lyons K**. Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery. *Mov Disord* 2000;15:467-473.
 41. Montgomery EB, **Lyons K**, Koller WC. Early detection of probable idiopathic Parkinson's disease:

- II. A prospective application of a diagnostic test battery. *Mov Disord* 2000;15:474-478.
42. Small JA, Kemper S, **Lyons K**. Sentence repetition and processing resources in Alzheimer's disease. *Brain Lang* 2000;75:232-258.
 43. Straits-Troster K, Fields JA, Wilkinson SB, Pahwa R, **Lyons KE**, Koller WC, Troster AI. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. *Brain Cogn* 2000;42:399-416.
 44. Brin MF, **Lyons KE**, Doucette J, Adler CH, Caviness J, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. *Neurology* 2001;56:1523-1528.
 45. Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, Lozano AM, Lang A, **Lyons K**, Koller W, Ghez C, Eidelberg D. Functional correlates of pallidal stimulation for Parkinson's disease. *Ann Neurol* 2001;49:155-164.
 46. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, **Lyons K**, Koller WC, Moeller JR, Eidelberg D. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. *Brain* 2001;124:1601-1609.
 47. Koller WC, **Lyons KE**, Wilkinson SB, Troster AI, Pahwa R. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. *Mov Disord* 2001;16:464-8.
 48. **Lyons KE**, Koller WC, Wilkinson SB, Pahwa R. Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor. *J Neurol Neurosurg Psychiatry* 2001;71:682-684.
 49. Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, **Lyons K**, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Ribble RC, Booze MW, Rogala A, Hauser MA, Zhang F, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Pericak-Vance MA, Vance JM. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. *JAMA* 2001;286:2245-2250.
 50. Milligan BD, Wilkinson S, Overman J, Kirschman DL, Koller WC, Pahwa R, **Lyons KE**, Batnitzky S, Gordon MA. Magnitude of microelectrode refinement in pallidotomy and thalamotomy. *Stereotact Funct Neurosurg* 2001;76:2-18.
 51. Pahwa R, **Lyons KE**, Wilkinson SB, Troster AI, Overman J, Kieltyka J, Koller WC. Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. *Mov Disord* 2001;16:140-143.
 52. Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, **Lyons K**, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Slotterbeck B, Booze MW, Ribble RC, Rampersaud E, West SG, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Vance JM, Pericak-Vance MA. Complete genomic screen in Parkinson disease. *JAMA* 2001;286:2239-2244.
 53. Tanner CM, Goldman SM, **Lyons KE**, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC. Essential tremor in twins: an assessment of genetic vs. environmental determinants of etiology. *Neurology* 2001;57:1389-1391.
 54. Woods SP, Fields JA, **Lyons KE**, Koller WC, Wilkinson SB, Pahwa R, Troster AI. Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a one-year follow-up. *Acta Neurochir* 2001;143:1273-1278.
 55. **Lyons KE**, Wilkinson SB, Troster AI, Pahwa R. Long-term efficacy of globus pallidus stimulation

- for the treatment of Parkinson's disease. *Stereotact Funct Neurosurg* 2002;79:214-220.
56. Pahwa R, **Lyons KE**, Kempf L, Wilkinson SB, Koller WC. Thalamic stimulation for midbrain tremor after partial hemangioma resection. *Mov Disord* 2002;17:404-407.
 57. Troster AI, Woods SP, Fields JA, **Lyons KE**, Pahwa R, Higginson CI, Koller WC. Neuropsychological deficits in essential tremor: an expression of cerebello-thalamo-cortical pathophysiology? *Eur J Neurol* 2002;9:143-151.
 58. Croyle KL, Troster AI, Fields JA, Straits-Troster KA, **Lyons KE**, Pahwa R. Presurgical coping, depression, and quality of life in persons with Parkinson's disease. *Journal of Clinical Psychology in Medical Settings* 2003;10:101-107.
 59. Fields JA, Troster AI, Woods SP, Higginson CI, Wilkinson SB, **Lyons KE**, Koller WC, Pahwa R. Neuropsychological and quality of life outcomes 12 months after unilateral thalamic stimulation for essential tremor. *J Neurol Neurosurg Psychiatry* 2003;74:305-311.
 60. **Lyons KE**, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. *Drug Saf* 2003;26:461-81.
 61. Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, **Lyons KE**, Pahwa R, Stern MB, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia FL, Stajich JM, Zhang F, Booze MW, Reaves JA, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM, Martin ER. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. *Arch Neurol* 2003;60:975-80.
 62. Pahwa R, **Lyons KE**. Essential tremor: differential diagnosis and current therapy. *Am J Med* 2003;115:134-142.
 63. Pahwa R, **Lyons KE**. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. *Mov Disord* 2003;18:584-587.
 64. Pahwa R, Wilkinson SB, Overman J, **Lyons KE**. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. *J Neurosurg* 2003;99:71-77.
 65. Troster AI, Fields JA, Wilkinson S, Pahwa R, Koller WC, **Lyons KE**. Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. *Stereotact Funct Neurosurg* 2003;80:43-47.
 66. van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, **Lyons K**, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Small GW, Mastaglia F, Roses AD, Stajich JM, Booze MW, Fujiwara K, Gibson RA, Middleton LT, Scott BL, Pericak-Vance MA, Vance JM. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. *Neurology* 2003;60:1189-1191.
 67. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, **Lyons K**, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. *Am J Hum Genet* 2003;72:804-811.
 68. Woods SP, Fields JA, **Lyons KE**, Pahwa R, Troster AI. Pulse width is associated with cognitive decline after thalamic stimulation for essential tremor. *Parkinsonism Relat Disord* 2003;9:295-300.
 69. Hauser RA, **Lyons KE**. Future therapies for Parkinson disease. *Neurol Clin* 2004;22(3 Suppl):S149-S166.
 70. Koller WC, **Lyons KE**, Truly W. Effect of levodopa treatment for parkinsonism in welders: A double-blind study. *Neurology* 2004;62:730-733.
 71. **Lyons KE**, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of

- subthalamic stimulation: a series of 160 procedures. *Neurology* 2004;63:612-616.
72. Okun MS, Fernandez HH, Pedraza O, Misra M, **Lyons KE**, Pahwa R, Tarsy D, Scollins L, Corapi K, Friehs GM, Grace J, Romrell J, Foote KD. Development and initial validation of a screening tool for Parkinson disease surgical candidates. *Neurology* 2004;63:161-163.
 73. Pahwa R, **Lyons KE**. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. *Neurol Clin* 2004;22(3 Suppl):S35-S52.
 74. Pahwa R, **Lyons KE**, Hauser RA. Ropinirole therapy for Parkinson's disease. *Expert Rev Neurother* 2004;4:581-588.
 75. Rakocevic G, **Lyons KE**, Wilkinson SB, Overman JW, Pahwa R. Bilateral pallidotomy for severe dystonia in an 18-month-old child with glutaric aciduria. *Stereotact Funct Neurosurg* 2004;82:80-83.
 76. Ushe M, Mink JW, Revilla FJ, Wernie A, Schneider Gibson P, McGee-Minnich L, Hong M, Rich KM, **Lyons KE**, Pahwa R, Perlmutter JS. Effect of stimulation frequency on tremor suppression in essential tremor. *Mov Disord* 2004;19:1163-1168.
 77. Lieberman A, **Lyons K**, Levine J, Myerburg R. Statins, cholesterol, co-enzyme Q10 and Parkinson's disease. *Parkinsonism Relat Disord* 2005;11:81-84.
 78. Liu W, McIntire K, Kim SH, Zhang J, Dascalos S, **Lyons KE**, Pahwa R. Quantitative assessments of the effect of bilateral subthalamic stimulation on multiple aspects of sensorimotor function for patients with Parkinson's disease. *Parkinsonism Relat Disord* 2005;11:503-508.
 79. **Lyons KE**, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. *J Neurosurg* 2005;103:252-255.
 80. Pahwa R, Wilkinson SB, Overman J, **Lyons KE**. Preoperative clinical predictors of response to bilateral subthalamic stimulation in patients with Parkinson's disease. *Stereotact Funct Neurosurg* 2005;83:80-83.
 81. Troster AI, Pahwa R, Fields JA, Tanner CM, **Lyons KE**. Quality of life in essential tremor questionnaire (QUEST): Development and initial validation. *Parkinsonism Relat Disord* 2005;11:367-373.
 82. Benabid AL, Deuschl G, Lang AE, **Lyons KE**, Rezai AR. Introduction: deep brain stimulation for Parkinson's disease. *Mov Disord* 2006;21(suppl 14):S168-S170.
 83. Davis JT, **Lyons KE**, Pahwa R. Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson's disease. *Clin Neurol Neurosurg* 2006;108:461-464.
 84. Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, **Lyons KE**, Rodriguez-Oroz MC, Tamma F, Troster AI, Vitek JL, Volkmann J, Voon V. Deep brain stimulation: postoperative issues. *Mov Disord* 2006;21(suppl 14):S219-S237.
 85. Eng ML, **Lyons KE**, Greene MS, Pahwa R. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson's disease outpatients: a pilot study on efficacy, tolerability, and quality of life. *J Altern Complement Med* 2006;12:395-399.
 86. Eng ML, **Lyons KE**, Pahwa R. Prevalence of bone mineral density screening in Parkinson's disease clinic outpatients. *Mov Disord* 2006;21:2265-2266.
 87. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, **Lyons KE**, Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. *Mov Disord* 2006;21(suppl 14):S290-S304.
 88. Lang AE, Houeto JL, Krack P, Kubu C, **Lyons KE**, Moro E, Ondo W, Pahwa R, Poewe W, Troster AI, Uitti R, Voon V. Deep brain stimulation: preoperative issues. *Mov Disord* 2006;21(suppl 14):S171-S196.
 89. Liu W, McIntire K, Kim SH, Zhang J, Dascalos S, **Lyons KE**, Pahwa R. Bilateral subthalamic stimulation improves gait initiation in patients with Parkinson's disease. *Gait Posture* 2006;23:492-

- 498.
90. Louis ED, Vonsattel JPG, Honig LS, Ross GW, **Lyons KE**, Pahwa R. Neuropathologic findings in essential tremor. *Neurology* 2006;66:1756-1759.
 91. **Lyons KE**, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease patients. *Clin Neuropharmacol* 2006; 29:73-76.
 92. **Lyons KE**, Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. *J Neurosurg* 2006;104:502-505.
 93. **Lyons KE**, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. *Clin Neuropharm* 2006;29:148-153.
 94. **Lyons KE**, Wilkinson SB, Pahwa R. Stimulation of the motor cortex for disabling essential tremor. *Clin Neurol Neurosurg* 2006;108:564-567.
 95. Pahwa R, Factor SA, **Lyons KE**, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006;66:983-995.
 96. Pahwa R, **Lyons KE**, Wilkinson SB, Simpson RK, Ondo WG, Tarsy D, Norregaard T, Hubble JP, Smith DA, Hauser RA, Jankovic J. Long-term evaluation of deep brain stimulation of the thalamus. *J Neurosurg* 2006;104:506-512.
 97. Ushe M, Mink JW, Tabbal SD, Hong M, Gibson PS, Rich KM, **Lyons KE**, Pahwa R, Perlmutter JS. Postural tremor suppression is dependent on thalamic stimulation frequency. *Mov Disord* 2006;21:1290-1292.
 98. Elble RJ, **Lyons KE**, Pahwa R. Levetiracetam is not effective for essential tremor. *Clin Neuropharmacol* 2007;30:350-356.
 99. Ishihara L, Gibson RA, Warren L, Amouri R, **Lyons K**, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari A, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, Gouider-Khouja N, Kefi M, Zouari M, Sassi SB, Yahmed SB, Euch-Fayeche GE, Middleton L, Burn DJ, Watts RL, Henati F. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. *Mov Disord* 2007;22:55-61.
 100. LeWitt PA, **Lyons KE**, Pahwa R on behalf of the SP-650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. *Neurology* 2007;68:1262-1267.
 101. Louis ED, Faust PL, Vonsattel JG, Honig LS, Rajput A, Robinson CA, Rajput A, Pahwa R, **Lyons KE**, Ross GW, Borden S, Moskowitz CB, Lawton A, Hernandez N. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain* 2007;130:3297-3307.
 102. **Lyons KE**, Davis JT, Pahwa R. Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa. *Stereotact Funct Neurosurg* 2007;85:169-174.
 103. **Lyons KE**, Pahwa R. Electronic motor function diary for patients with Parkinson's disease: a feasibility study. *Parkinsonism Relat Disord* 2007;13:304-307.
 104. Pahwa R, Stacy MA, Factor SA, **Lyons KE**, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL on behalf of the EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. *Neurology* 2007;68:1108-1115.
 105. Vela L, **Lyons KE**, Singer C, Lieberman AN. Pain-pressure threshold in patients with Parkinson's disease with and without dyskinesia. *Parkinsonism Relat Disord* 2007;13:189-192.
 106. Axelrad JE, Louis ED, Honig LS, Flores I, Ross W, Pahwa R, **Lyons KE**, Faust PL, Vonsattel JG. Reduced purkinje cell number in essential tremor: a postmortem study. *Arch Neurol* 2008;65:101-

- 107.
107. **Lyons KE**, Pahwa R. Deep brain stimulation and tremor. *Neurotherapeutics* 2008;5:331-338.
 108. **Lyons KE**, Pahwa R. Pharmacotherapy of essential tremor: an overview of existing and upcoming agents. *CNS Drugs* 2008;22:1037-1045.
 109. Muniz AS, Nobre FF, Liu H, **Lyons KE**, Pahwa R, Liu W, Nadal J. Assessment of the effects of subthalamic stimulation in Parkinson disease patients by artificial neural network. *Conf Proc IEEE Eng Med Biol Soc* 2008;1:4700-4703.
 110. Chen JJ, Swope DM, Dashtipour K, **Lyons KE**. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. *Pharmacotherapy* 2009;29:1452-1467.
 111. Hauser RA, **Lyons KE**, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. *Mov Disord* 2009;24:979-983.
 112. LeWitt PA, Jennings D, **Lyons KE**, Pahwa R, Rabinowicz AL, Wang J, Guarnieri M, Hubble JP, Murck H. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. *Mov Disord* 2009;24:1319-1324.
 113. Louis ED, Faust PL, Vonsattel JPG, Honig LS, Henchcliffe C, Pahwa R, **Lyons KE**, Rios E, Erickson-Davis C, Moskowitz CB, Lawton A. Older onset essential tremor: more rapid progression and more degenerative pathology. *Mov Disord* 2009;24:1606-1612.
 114. Louis ED, Faust PL, Vonsattel JPG, Honig LS, Rajput A, Rajput A, Pahwa R, **Lyons KE**, Ross WG, Elble RJ, Erickson-Davis C, Moskowitz CB, Lawton A. Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. *Mov Disord* 2009;24:1600-1605.
 115. Lundervold DA, Pahwa R, **Lyons KE**. Effect of behavioral intervention on comorbid general anxiety disorder and Parkinson's disease. *Clinical Gerontologist* 2009;32:104-117.
 116. **Lyons KE**, Pahwa R. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. *Mov Disord* 2009;24:2121-2127.
 117. McVey MA, Stylianou AP, Luchies CW, **Lyons KE**, Pahwa R, Jernigan S, Mahnken JD. Early biomechanical markers of postural instability in Parkinson's disease. *Gait Posture* 2009;30:538-542.
 118. Muniz AMS, Liu W, Liu H, **Lyons KE**, Pahwa R, Nobre FF, Nadal J. Assessment of the effects of subthalamic stimulation in Parkinson disease patients by artificial neural network. *Conf Proc IEEE Eng Med Biol Soc* 2009;1:5673-5676.
 119. Nashatizadeh M, **Lyons KE**, Pahwa R. A review of ropinirole prolonged release in Parkinson's disease. *Clin Interv Aging* 2009;4:179-186.
 120. Novak P, Klemp JA, Ridings LW, **Lyons KE**, Pahwa R, Nazzaro JM. Effect of deep brain stimulation of the subthalamic nucleus upon the contralateral subthalamic nucleus in Parkinson disease. *Neurosci Lett* 2009;463:12-16.
 121. Pahwa R, **Lyons KE**. Levodopa-related wearing-off in Parkinson's disease: identification and management. *Curr Med Res Opin* 2009;25:841-849.
 122. Simuni T, **Lyons KE**, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 1. *Eur Neurol* 2009;61:193-205.
 123. Simuni T, **Lyons KE**, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 2. *Eur Neurol* 2009;61:206-215.
 124. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, **Lyons KE**, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Occupation and risk of parkinsonism: a multicenter case-control study. *Arch Neurol* 2009;66:1106-1113.
 125. Weintraub D, Hoops S, Shea JA, **Lyons KE**, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza

- MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig JI, Colcher A, Horn SS, Stern MB, Voon V. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. *Mov Disord* 2009;24:1461-1467.
126. Esteves AR, Lu J, Rodova M, Onyango I, Lezi E, Dubinsky R, **Lyons KE**, Pahwa R, Burns JM, Cardoso SM, Swerdlow RH. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. *J Neurochem* 2010;113:674-682.
 127. Hanna-Pladdy B, Enslein A, Fray M, Gajewski BJ, Pahwa R, **Lyons KE**. Utility of the Neuro Trax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and MoCA. *Int J Neurosci* 2010;120:538-543.
 128. Louis ED, Erickson-Davis C, Pahwa R, **Lyons KE**, Garber A, Moskowitz CB, Lawton A, Faust PL, Vonsattel JPG. Essential tremor with ubiquitinated Purkinje cell intranuclear inclusions. *Acta Neuropathol* 2010;119:375-377.
 129. **Lyons KE**, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. *Clin Neuropharm* 2010;33:5-10.
 130. Muniz AMS, Liu H, **Lyons KE**, Pahwa R, Liu W, Nobre FF, Nadal J. Comparison among probabilistic neural network, support vector machine and logistic regression for evaluating the effect of subthalamic stimulation in Parkinson disease on ground reaction force during gait. *J Biomech* 2010;43:720-726.
 131. Nazzaro JM, **Lyons KE**, Wetzel LH, Pahwa R. Use of brain MRI after deep brain stimulation hardware implantation. *Int J Neurosci* 2010;120:176-183.
 132. Pahwa R, **Lyons KE**. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. *Am J Manag Care* 2010;16:S94-S99.
 133. Watts RL, **Lyons KE**, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl N on behalf of the 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. *Mov Disord* 2010;25:858-866.
 134. Muniz AMS, Liu H, **Lyons KE**, Pahwa R, Liu W, Nadal J. Quantitative evaluation of the effects of subthalamic stimulation on gait in Parkinson's disease patients using principal component analysis. *Int J Neurosci* 2010;120:609-616.
 135. Vitek JL, **Lyons KE**, Bakay R, Benabid AL, Deuschl G, Hallett M, Kurlan R, Pancrazio JJ, Rezai A, Walter BL, Lang AE. Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). *Mov Disord* 2010;25:1530-1537.
 136. Hammer MJ, Barlow SM, **Lyons KE**, Pahwa R. Subthalamic nucleus deep brain stimulation changes speech respiratory and laryngeal control in Parkinson's disease. *J Neurol* 2010;257:1692-1702.
 137. Nazzaro JM, **Lyons KE**, Honea RA, Mayo MS, Cook-Wiens G, Harsha A, Burns JM, Pahwa R. Head positioning and risk of pneumocephalus, air embolism, and hemorrhage during subthalamic deep brain stimulation surgery. *Acta Neurochir* 2010;152:2047-2052.
 138. Muniz AMS, Liu W, Liu H, **Lyons KE**, Pahwa R, Nadal J. Gait initiation evaluation after deep brain stimulation for Parkinson's disease: a 7-year follow-up. *Conf Proc IEEE Eng Med Biol Soc* 2010;1:3650-3653.
 139. Hammer MJ, Barlow SM, **Lyons KE**, Pahwa R. Subthalamic nucleus deep brain stimulation changes velopharyngeal control in Parkinson's disease. *J Commun Disord* 2011;44:37-48.
 140. Nishioka K, Ross OA, Vilarino-Guell C, Cobb SA, Kachergus JM, Mann DMA, Snowden J, Richardson AMT, Neary D, Robinson CA, Rajput A, Papapetropoulos S, Mash DC, Pahwa R, **Lyons KE**, Wszolek ZK, Dickson DW, Farrer MJ. Glucocerebrosidase mutations in diffuse Lewy body disease. *Parkinsonism Relat Disord* 2011;17:55-57.

141. Aminoff MJ, Christine CW, Friedman JH, Chou KL, **Lyons KE**, Pahwa R, Bloem BR, Parashos SA, Price CC, Malaty IA, Iansek R, Bodis-Wollner I, Suchowersky O, Oertel WH, Zamudio J, Oberdorf J, Schmidt P, Okun MS for the National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. *Parkinsonism Relat Disord* 2011;17:139-145.
142. Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, Pahwa R, **Lyons KE**, Uitti RJ, Wszolek ZK, Dickson DW, Farrer MJ, Ross OA. *MAPT* H1 Haplotype is a risk factor for essential tremor and multiple system atrophy. *Neurology* 2011;76:670-672.
143. Papay K, Mamikonyan E, Siderowf AD, Duda JE, **Lyons KE**, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. *Parkinsonism Relat Disord* 2011;17:153-155.
144. McDowd J, Hoffman L, Rozek E, **Lyons KE**, Pahwa R, Burns J, Kemper S. Understanding verbal fluency in healthy aging, Alzheimer's disease and Parkinson's disease. *Neuropsychology* 2011;25:210-225.
145. Go CL, Rosales RL, Schmidt P, **Lyons KE**, Pahwa R, Okun MS. Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review. *Parkinsonism Relat Disord* 2011;17:308-312.
146. Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, **Lyons KE**, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS. Hospitalization in Parkinson disease: a survey of the National Parkinson Foundation Centers. *Parkinsonism Relat Disord* 2011;17:440-445.
147. Nazzaro JM, Pahwa R, **Lyons KE**. The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson's disease. *Parkinsonism Relat Disord* 2011;17:606-609.
148. Stylianou AP, McVey MA, **Lyons KE**, Pahwa R, Luchies CW. Postural sway in patients with mild to moderate Parkinson's disease. *Int J Neurosci* 2011;121:614-621.
149. **Lyons KE**, Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. *Am J Manag Care* 2011;17:S308-S314.
150. Nazzaro JM, **Lyons KE**, Pahwa R, Ridings LW. The importance of testing deep brain stimulation lead impedances before final lead implantation. *Surg Neurol Int* 2011;2:131.
151. Pahwa R, **Lyons KE**. Current issues in the diagnosis and treatment of Parkinson's disease: Introduction. *Int J Neurosci* 2011;121(suppl 2):1-2.
152. **Lyons KE**, Pahwa R. Diagnosis and initiation of treatment in Parkinson's disease. *Int J Neurosci* 2011;121(suppl 2):27-36.
153. Searl J, Wilson K, Haring K, Dietsch A, **Lyons K**, Pahwa R. Feasibility of group voice therapy for individuals with Parkinson's disease. *J Comm Disord* 2011;44:719-732.
154. Martinez-Martin P, Jeukens-Visser M, **Lyons KE**, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. *Mov Disord* 2011;26:2371-2380.
155. Goldman SM, Kamel F, Ross W, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, **Lyons KE**, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Head injury, alpha-synuclein Rep 1 and Parkinson's disease. *Ann Neurol* 2012;71:40-48.
156. Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, **Lyons KE**, Troster AI, Vitek JL, Tagliati M for the SJM DBS

- Study Group. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomized controlled trial. *Lancet Neurol* 2012;11:140-149.
157. Clair AA, **Lyons KE**, Hamburg J. A feasibility study of the effects of music and movement on physical function, quality of life, depression and anxiety in patients with Parkinson disease. *Music Med* 2012;4:49-55.
 158. Muniz AMS, Nadal J, **Lyons KE**, Pahwa R, Liu W. Long-term evaluation of gait initiation in six Parkinson's disease patients with bilateral subthalamic stimulation. *Gait Posture* 2012;35:452-457.
 159. Hauser RA, **Lyons KE**, Pahwa R. The UPDRS-8: A brief assessment scale for Parkinson's disease. *Int J Neurosci* 2012;122:333-337.
 160. Nazzaro JM, Pahwa R, **Lyons KE**. Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. *J Neurosurg* 2012;117:156-61.
 161. Bradberry TJ, Verhagen Metman L, Contreras-Vidal JL, van den Munckhof P, Hosey LA, Thompson JLW, Schulz GM, Lenz F, Pahwa R, **Lyons KE**, Braun AR. Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: An H₂¹⁵O PET study. *Brain Stimul* 2012;5:605-615.
 162. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, LeWitt P, **Lyons K**, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. *Mov Disord* 2012;27:1567-1569.

Study Group Publications

1. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M-X, Phelps CH and the Alzheimer's Disease Centers Consortium on APOE and Alzheimer's Disease. Utility of the Apolipoprotein-E genotype in the diagnosis of Parkinson's disease. *N Engl J Med*, 1998;338:506-511.
2. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson's disease in a sample without parkin mutations. *Am J Hum Genet* 2002;71:124-135.
3. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC and the Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson's disease. *Neurology* 2003;60:796-801.
4. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T and the Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. *Hum Mol Genet* 2003;12:2599-2608.
5. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults, Conneally PM, Foroud T and the Parkinson Study Group. Significant linkage of Parkinson disease to chromosome 2q36-37. *Am J Hum Genet* 2003;72:1053-1057.
6. Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T and the Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease. *Mov Disord* 2003;18:275-279.
7. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T and the Parkinson Study Group. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. *Mov Disord* 2004;19:649-655.
8. Pankratz N, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. *Neurology* 2004;62:1616-1618.

9. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. *N Engl J Med* 2004;351:2498-508.
10. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T for the Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. *Lancet* 2005;365:410-412.
11. Ondo WG, Bronte-Stewart H for the DBS Study Group. The North American survey of placement and adjustment strategies for deep brain stimulation. *Stereotact Funct Neurosurg* 2005;83:142-147.
12. Elble RJ for the Tremor Research Group and Conference Attendees. Report from a U.S. conference on essential tremor. *Mov Disord* 2006;21:2052-2061.
13. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R and the Tremor Research Group. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. *Brain* 2006;129:2660-2666.
14. Foroud T, Pankratz N, Martinez M and the PROGENI/GSPD-European Consortium. Chromosome 5 and Parkinson disease. *Eur J Hum Genet* 2006;14:1106-1110.
15. Huntington Study Group PHAROS Investigators. At risk for Huntington disease. The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. *Arch Neurol* 2006;63:991-998.
16. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology* 2006;66:664-671.
17. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group – PROGENI Investigators. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. *Mov Disord* 2006;21:45-49.
18. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group – PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson's disease. *Mov Disord* 2006;21:2257-2260.
19. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group – PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. *Neurosci Lett* 2006;408:209-213.
20. Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. *Arch Neurol* 2006;63:210-216.
21. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC on behalf of the NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease using futility studies. *Neurology* 2006;66:628-633.
22. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Frasier D, Deppen P, Brocht A, Weaver C, Bennett S for NINDS NET-PD Investigators and Coordinators. Self-reported adherence versus pill count in Parkinson's disease: The NET-PD experience. *Mov Disord* 2007; 22: 822-827.
23. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T for the Parkinson Study Group-PROGENI Investigators. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. *Neurology* 2007;69:1737-1744.
24. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T and The Parkinson Study Group – PROGENI Investigators. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. *Mov Disord* 2007;22:254-257.
25. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early

- Parkinson disease. *Neurology* 2007;68:20-28.
26. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. *Clin Neuropharmacol* 2008;31:141-150.
 27. Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T for the Parkinson's Study Group – PROGENI Investigators. Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord* 2008;23:2216-2223.
 28. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S and the Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naïve subjects with Parkinson disease. *Neurology* 2008;71:481-485.
 29. Hauser RA, Auinger P, Oakes D on behalf of the Parkinson Study Group. Levodopa response in early Parkinson's disease. *Mov Disord* 2009;24:2328-2336.
 30. Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T and the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for onset age in Parkinson disease. *BMC Med Genet* 2009;10:98.
 31. Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I on behalf of the Huntington Study Group. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. *Neurology* 2009;73:385-392.
 32. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, for the Parkinson Study Group – PROGENI Investigators. Variation in GIGYF2 is not associated with Parkinson disease. *Neurology* 2009;72:1886-1892.
 33. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, for the Parkinson Study Group – PROGENI Investigators. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. *Neurology* 2009;72:310-316.
 34. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, for the Parkinson Study Group – PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. *Neurology* 2009;73:279-286.
 35. Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Pfeiffer RF, Foroud T for the Parkinson Study Group – PROGENI Investigators. Alpha-synuclein and familial Parkinson's disease. *Mov Disord* 2009;24:1125-1131.
 36. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH and the PSG-PROGENI and Gene PD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. *Hum Genet* 2009;124:593-605.
 37. Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM for the NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. *Arch Neurol* 2009;66:1099-1104.
 38. Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I and the Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. *Mov Disord* 2009;24:2081-2090.
 39. Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS for the National Parkinson Foundation DBS Working Group. Safety of MRI in patients with implanted deep brain stimulation

- devices. *Neuroimage* 2009;47(suppl 2):T53-57.
40. Elble RJ, Biondi DM, Ascher S, Wiegand F, Hulihan J (EPY2008 Study Group). Carisbamate in essential tremor: brief report of a proof of concept study. *Mov Disord* 2010;25:634-638.
 41. Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B on behalf of the NINDS NET-PD Investigators. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. *Mov Disord* 2010;15:1082-1086.
 42. Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T, the Parkinson Study Group – PROGENI Investigators. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. *BMC Med Genet* 2010;11:53.
 43. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg G. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet* 2011;43:699-705.
 44. Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL, the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. *PLoS ONE*;2011;6(8):e20988.
 45. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T, and the PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Ann Neurol* 2012;71:370-384.
 46. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide B-MM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP, 23andMe, The Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium, The International Parkinson's Disease Genomics Consortium (IPDGC), The Parkinson's Disease GWAS Consortium, The Wellcome Trust Case Control Consortium 2 (WTCCC2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JPA, Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. *PLoS Genet*. 2012 Mar;8(3):e1002548.
 47. Kang UJ, Auinger P, on behalf of the Parkinson Study Group ELLDOPA Investigators. Activity enhances dopaminergic long-duration response in Parkinson disease. *Neurology* 2012;78:1146-1149.
 48. Elm JJ, The NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. *Mov Disord* 2012;27:1513-1521.

Invited Publications and Chapters

1. Kemper S, Lyons KE. The effects of Alzheimer's dementia on language and communication. In

- M.L. Hummert, J. Wieman, & J Nussbaum (Eds.) *Interpersonal communication and older adulthood: Interdisciplinary Theory and Research*, Sage: Newbury Park, CA, 1994.
2. Koller WC, Pahwa R, **Lyons KE**, Albanese A. Surgical treatment of Parkinson's disease. *J Neurol Sci* 1999;167:1-10.
 3. Troster AI, **Lyons KE**, Straits-Troster, KA. Determinants of health-related quality of life changes in Parkinson's disease. In Martin PM, Koller WC, *Quality of life in Parkinson's disease*, Barcelona: MASSON SA, 1999.
 4. Koller WC, Pahwa R, **Lyons KE**, Wilkinson SB. Deep brain stimulation of the Vim nucleus of the thalamus for the treatment of tremor. *Neurology* 2000;55(Suppl 6):S29-S33.
 5. Pahwa R, **Lyons K**, Koller WC. Surgical treatment of essential tremor. *Neurology* 2000;54(Suppl. 4):S39-S44.
 6. Pahwa R, **Lyons KE**. Deep brain stimulation in Parkinson's disease. *Adv Clin Neurosci* 2001;11:95-105.
 7. Koller WC, **Lyons K**, Pahwa R, Wilkinson S: Thalamic stimulation. In Factor SA, Weiner WJ (eds.), *Parkinson's Disease: Diagnosis and Clinical Management*. Demos Medical Publishing: New York, NY, 2002, 553-557.
 8. Koller WC, Minagar A, **Lyons KE**, Pahwa R. Surgical treatment of Parkinson's disease: past, present and future. In Tarsy D, Vitek JL, Lozano AM (eds), *Surgical treatment of Parkinson's disease and other movement disorders*. Humana Press: Totowa, NJ, 2002:41-50.
 9. Pahwa R, **Lyons KE**. Solving the puzzle of Parkinson's therapy. *Prac Neurol* 2002; Feb:17-24.
 10. Pahwa R, **Lyons K**. See the big picture when treating Parkinson's disease. *Prac Neurol* 2002;Apr:26-31.
 11. Pahwa R, **Lyons KE**. Deep brain stimulation in Parkinson's disease. In Pahwa, Lyons Koller (eds), *Handbook of Parkinson's Disease* (3rd ed), Marcel Dekker: New York, NY: 2003:497-515.
 12. Pahwa R, **Lyons K**. What to do when levodopa doesn't control PD symptoms. *Practical Neurology* 2003;June:32-35.
 13. Lieberman A, **Lyons K**. Anxiety worsens symptoms of Parkinson disease. In Korczyn AD (convenor) *Mental Dysfunctions in Parkinson's Disease*, Salzburg (Austria), October 24-27, 2004. Medimond International Proceedings: Bologna, Italy, 2004:51-58.
 14. Lieberman A, **Lyons K**, Okun M. Depression in Parkinson disease. In Korczyn AD (convenor) *Mental Dysfunctions in Parkinson's Disease*, Salzburg (Austria), October 24-27, 2004. Medimond International Proceedings: Bologna, Italy, 2004:59-67.
 15. Lieberman A, **Lyons K**, Levine J. Do Statins worsen Parkinson disease? In Korczyn AD (convenor) *Mental Dysfunctions in Parkinson's Disease*, Salzburg (Austria), October 24-27, 2004. Medimond International Proceedings: Bologna, Italy, 2004:167-169.
 16. **Lyons KE**, Pahwa R. Deep brain stimulation and essential tremor. *J Clin Neurophysiol* 2004;21:2-5.
 17. **Lyons KE**, Pahwa R. Deep brain stimulation in Parkinson's disease. *Curr Neurol Neurosci Rep* 2004;4:290-295.
 18. **Lyons KE**, Pahwa R, Rabey JM. Bromocriptine. In Pahwa, Lyons, Koller (eds) *Therapy of Parkinson's Disease* (3rd Ed). Marcel Dekker: New York, NY, 2004:105-113.
 19. **Lyons KE**, Pahwa R. Amantadine. In Ebadi M, Pfeiffer RF (eds). *Parkinson's Disease*. CRC Press: Boca Raton: FL, 2005:685-690.
 20. Pahwa A, **Lyons KE**, Pahwa R. Medical Treatment of Essential Tremor. In Lyons KE, Pahwa R (eds) *Handbook of Essential Tremor and Other Tremor Disorders*. Taylor & Francis: Boca Raton, FL, 2005:145-160.
 21. Pahwa R, **Lyons KE**. Parkinson's disease: management of motor and nonmotor symptoms. In

- Parkinson's Disease Management Guide, PDR 2005, 5th Edition*. Thomson PDR: New Jersey, 2005: 101-126.
22. Pahwa R, **Lyons KE**. Parkinson's disease; management of motor and nonmotor symptoms. In *Parkinson's Disease Management Guide, PDR 2006, 6th Edition*. Thomson PDR: New Jersey, 2005:101-128.
 23. **Lyons KE**, Pahwa R. Surgery for Parkinson's disease. In RA Hauser (ed) *Parkinson's Disease Questions and Answers, 5th Edition*. Merit Publishing International: West Palm Beach, FL, 2006:161-182.
 24. Pahwa R, **Lyons KE**. Parkinson's disease; management of motor and nonmotor symptoms. In *Parkinson's Disease Management Guide, PDR 2007, 7th Edition*. Thomson PDR: New Jersey, 2006: 101-128.
 25. Dalvi A, **Lyons KE**, Pahwa R. Secondary dystonia. In Stacy MA (ed), *Handbook of Dystonia*. Informa Healthcare: New York, NY, 2007;245-266.
 26. **Lyons KE**, Pahwa R. Deep brain stimulation. In Pahwa R, Lyons KE (eds). *Handbook of Parkinson's Disease, 4th Ed*. Informa Healthcare: New York, NY, 2007:409-421.
 27. **Lyons KE**, Pahwa R. Deep brain stimulation for Parkinson's disease. In US Neurological Disease 2006 Issue II – January 2007. Touch Briefings: London, 2007:29-34.
 28. **Lyons KE**, Pahwa R. Ropinirole 24-h prolonged release in advanced Parkinson disease: review of a randomized, double-blind, placebo-controlled study (EASE-PD – Adjunct Study). In Cummings JL (ed), *Progress in Neurotherapeutics and Neuropsychopharmacology*, Volume 3. Cambridge University Press: Cambridge, 2008, 73-84.
 29. **Lyons KE**, Pahwa R. Thalamic deep brain stimulation and essential tremor. In Tarsy D, Vitek JL, Starr PA, Okun MS (eds), *Deep Brain Stimulation in Neurological and Psychiatric Disorders*. Humana Press: Totowa, NJ, 2008, 205-214.
 30. Pahwa R, **Lyons KE**. A stimulating treatment for essential tremor. In Reich SG (ed), *Movement Disorders: 100 Instructive Cases*. Informa Healthcare: London, 2008, 321-323.
 31. Tarsy D, Papavassiliou E, **Lyons KE**, Pahwa R. Thalamic deep brain stimulation for Parkinson's disease. In Tarsy D, Vitek JL, Starr PA, Okun MS (eds), *Deep Brain Stimulation in Neurological and Psychiatric Disorders*. Humana Press: Totowa, NJ, 2008, 229-241.
 32. **Lyons KE**, Pahwa R. Management of motor disability in advanced Parkinson's disease. In Simuni T, Pahwa R (eds). *Parkinson's Disease, Oxford American Neurology Library*. Oxford University Press: New York, NY, 2009, 71-82.
 33. Nazzaro JM, **Lyons KE**, Pahwa R. Management of essential tremor. In Lozano AM, Gildenberg PL, Tasker RR (eds), *Textbook of Stereotactic and Functional Neurosurgery*. Springer: Berlin, 2009, 1743-1755.
 34. Pahwa R, **Lyons KE**. Parkinsonism. In Rakel RE, Bope ET (eds), *Conn's Current Therapy 2009*. Saunders Elsevier: Philadelphia, PA, 2009, 952-958.
 35. Pahwa R, **Lyons KE**. Parkinsonism. In Bope ET, Rakel RE, Kellerman R (eds), *Conn's Current Therapy 2010*. Saunders Elsevier: Philadelphia PA, 2010, 960-965.
 36. Nashatizadeh MM, **Lyons KE**, Pahwa R. Postural Tremor. In Kompoliti K, Verhagen ML (eds.), *Encyclopedia of Movement Disorders, volume 3*. Academic Press: Oxford, 2010:466-470.
 37. Nashatizadeh MM, **Lyons KE**, Pahwa R. Rest Tremor. In Kompoliti K, Verhagen ML (eds.), *Encyclopedia of Movement Disorders, volume 2*. Academic Press: Oxford, 2010:29-32.
 38. Pahwa R, **Lyons KE**. Managing essential tremor patients with deep brain stimulation. In Marks WJ (ed.), *Deep Brain Stimulation Management*. Cambridge University Press: Cambridge, 2011:56-61.
 39. Pahwa R, **Lyons KE**. Parkinsonism. In Bope ET, Kellerman R, Rakel RE (eds), *Conn's Current*

Therapy 2011. Elsevier Saunders: Philadelphia, 2011:973-978.

40. Pahwa R, **Lyons KE**. Infectious, postinfectious, toxin-induced, and drug-induced parkinsonism. In Watts RL, Standaert DG, Obeso JA (eds), *Movement Disorders, 3rd Ed*. McGraw-Hill:New York, 2012:461-480.
41. **Lyons KE**. Essential tremor. In Watts RL, Standaert DG, Obeso JA (eds), *Movement Disorders, 3rd Ed*. McGraw-Hill:New York, 2012:461-480.
42. Pahwa R, **Lyons KE**. Parkinsonism. In Bope ET, Kellerman R, Rakel RE (eds), *Conn's Current Therapy 2012*. Elsevier Saunders: Philadelphia, 2012:633-638.
43. Dalvi A, **Lyons KE**, Pahwa R. Secondary dystonia. In Stacy MA (ed), *Handbook of Dystonia, 2nd Ed*. Informa Healthcare: London, 2012:251-275.
44. Martinez-Martin P, Rodriguez-Blazquez C, **Lyons KE**. Quality of life scales. In Sampaio C, Goetz CG, Schrag A (eds), *Rating Scales in Parkinson's Disease: Clinical Practice and Research*. Oxford University Press: New York, 2012:123-144.
45. **Lyons KE**, Pahwa R. Amantadine. In Pfeiffer RF, Wszolek ZK, Ebadi M (eds), *Parkinson's Disease 2nd Edition*. CRC Press: Boca Raton, 2013:819-824.

Abstracts

1. **Lyons KE**, Kellas G, Martin M (1992). Individual differences in semantic priming among older adults. Presented at the Fourth Annual Cognitive Aging Conference, Atlanta, GA.
2. **Lyons KE**, Kemper S, Ferraro FR, Balota D, LaBarge E, Storandt M (1993). Language and Alzheimer's Disease: A reduction in syntactic complexity. Presented at the 1993 Convention of the American Psychological Society, Chicago, IL.
3. Koller WC, Pahwa R, **Lyons K**, Smith D (1994). Low dose clozapine in the treatment of levodopa-induced psychosis. Presented at the 3rd International Congress of Movement Disorders, Orlando, FL. *Mov Disord 1994;9(suppl 1):64*.
4. **Lyons KE**, Pahwa R, McGuire D, Koller WC (1994). Comparison of patient diaries and the UPDRS in the evaluation of motor fluctuations in Parkinson's disease. Presented at the 3rd International Congress of Movement Disorders, Orlando, FL. *Mov Disord 1994;9(suppl 1):75*.
5. Pahwa R, **Lyons K**, Hubble J, Koller WC (1994). Subtypes of PD: Determines motor and cognitive prognosis. Presented at the 3rd International Congress of Movement Disorders, Orlando, FL. *Mov Disord 1994;9(suppl 1):81*.
6. Pahwa R, **Lyons K**, Silverstein P, Zwiebel F, Marjama J, Ward R, Koller WC (1994). Clinical experience with generic carbidopa/levodopa (G-L) in patients with Parkinson's disease (PD). Presented at the 46th Annual Meeting of the American Academy of Neurology, Washington, D.C. *Neurology 1994;44(suppl 2):A244*.
7. Anouti A, Golbe L, Schmidt K, **Lyons K**, Koller WC, Schellenberg G (1995). Apo E genotypes in progressive supranuclear palsy. Presented at the 47th Annual Meeting of the American Academy of Neurology, Seattle, WA. *Neurology 1995;45(suppl 4):A255*.
8. Glatt SL, Hubble JP, Pahwa R, Hassanein RES, **Lyons KE**, Paolo A, Troster A, Sissel J, Koller WC (1995). Factors predictive of mild cognitive impairment in Parkinson's disease. Presented at the ninth annual Symposium on Etiology, Pathogenesis, and prevention of Parkinson's Disease, Washington, DC. *Mov Disord 1995;10:692*.
9. Handler MS, Glatt S, Hubble J, Pahwa R, **Lyons KE**, Koller WC (1995). Clinical diagnostic accuracy in the University of Kansas Alzheimer's Disease Center. Presented at the American Academy of Neuro-Pathology San Antonio, TX.

10. Handler MS, **Lyons KE**, Pahwa R, Glatt S, Hubble J, Koller WC (1995). Cortical Lewy bodies (LB) and Tangles: Relationship to cognitive impairment in Parkinson's disease (PD). Presented at the 47th Annual Meeting of the American Academy of Neurology, Seattle, WA. *Neurology 1995;45(suppl 4):A239*.
11. Koller WC, Barnes P, **Lyons K**, Busenbark KL (1995). Validation of a screening tool for Essential Tremor. Presented at the 47th Annual Meeting of the Academy of Neurology, Seattle, WA. *Neurology 1995;45 (suppl 4):A253*.
12. **Lyons KE**, Pahwa R, Glatt S, Hubble J, Koller WC (1995). Rate of change of cognitive status in Alzheimer's and Parkinson's disease. Poster presented at the 47th Annual Meeting of the American Academy of Neurology, Seattle, WA. *Neurology 1995;45(suppl 4):A196*.
13. **Lyons KE**, Pahwa R, Hubble JP, Koller WC (1995). Increased frequency of a family history of Parkinson's disease (PD) in Young versus older onset PD. Presented at the ninth annual Symposium on Etiology, Pathogenesis, and prevention of Parkinson's Disease, Washington, DC. *Mov Disord 1995;10:695*.
14. Pahwa R, **Lyons K**, Hubble J, Paolo A, Karst A, Villagra F, Glatt S, Koller, WC (1995). Hallucinations in Parkinson's disease patients correlate with cognitive impairment. Presented at the 9th annual Symposium on Etiology, Pathogenesis, and prevention of Parkinson's Disease, Washington, DC. *Mov Disord 1995;10:695*.
15. Pahwa R, **Lyons K**, McGuire D, Koller WC (1995). Early morning akinesia in Parkinson's Disease (PD): Effect of standard carbidopa/levodopa (Std-L) and controlled-release carbidopa/levodopa. Presented at the 47th Annual Meeting of the Academy of Neurology, Seattle, WA. *Neurology 1995;45(suppl 4):A252*.
16. Small JA, Kemper S, **Lyons K** (1995). Facilitating sentence comprehension in Alzheimer's disease. Presented at the Gerontological Society of America's 48th Annual Scientific Meeting Program, Los Angeles, CA.
17. Troster AI, Paolo AM, Glatt SL, **Lyons KE**, Koller WC (1995). Depression and cognitive impairment in Parkinson's disease. Presented at the 23rd Annual Meeting of the International Neuropsychological Society, Seattle, WA. *J Intl Neuropsych Soc 1995;1:153*.
18. Busenbark K, Wilkinson S, **Lyons K**, Koller WC, Hubble JP (1996). Quality of life in thalamic stimulation for tremor as measured by the Sickness Impact Profile. Presented at the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA. *Neurology 1996;46(suppl):A372*.
19. Glatt S, Pahwa R, **Lyons K**, Handler M, Karst A, Koller WC (1996). Paraplegia in flexion: Clinical and pathologic correlates. Presented at the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA. *Neurology 1996;46(suppl):A248*.
20. Hubble JP, Busenbark K, **Lyons K**, Wilkinson S, Paulson GW, Koller WC (1996). Effects of deep brain stimulation (DBS) on tremor type and diagnosis. Presented at the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA. *Neurology 1996;46:A401*.
21. Hubble JP, **Lyons K**, Busenbark K, Pahwa R, Koller W (1996). Essential Tremor: Influence of gender on phenotype. Presented at the 10th Annual Symposium on Hyperkinetic Movement Disorders, Miami, FL. *Mov Disord 1996;11:596*.
22. **Lyons KE**, Koller WC, Pahwa R (1996). Gender differences in Parkinson's Disease. Presented at the 4th International Congress of Movement Disorders, Vienna Austria. *Mov Disord 1996;11(suppl 1):161*.
23. McCollam KM, Embretson SE, **Lyons K** (1996). A psychometric model identifying age-related decline in spatial ability. Presented at the annual meeting of the American Psychological Association, Toronto, Canada.
24. Pahwa R, **Lyons K**, Glatt S, Paolo T, Troster A, Koller WC, Karst A, Hubble J (1996). Parkinson's disease dementia: Sensitivity and specificity of various diagnostic criteria and measures. Presented at

- the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA. *Neurology* 1996;46(suppl):A143.
25. Pahwa R, **Lyons K**, McGuire D, Silverstein P, Zwiebel F, Robischon M, Cubberley V, Koller WC. (1996). Clinical pharmacokinetic and quality of life parameters in PD subjects on standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Presented at the 4th International Congress of Movement Disorders, Vienna Austria. *Mov Disord* 196;11(suppl 1):199.
 26. Pahwa R, Wilkinson S, Smith D, **Lyons K**, Koller WC. (1996). High frequency pallidal stimulation in Parkinson's disease (PD). Presented at the 121st Annual Meeting of the American Neurological Association, Miami, FL. *Ann Neurol* 1996;40:533.
 27. Small JA, **Lyons K**, Kemper S. (1996). Grammatical abilities in Alzheimer's disease and Parkinson's disease. Presented at the Sixth Cognitive Aging Conference, Atlanta, GA.
 28. Villagra F, **Lyons K**, Koller WC, Wilkinson SB, Overman J, Hubble JP, Busenbark K, Dubinsky R (1996). The lack of rebound effect on tremor in Parkinson's disease and Essential Tremor patients that have undergone VIM thalamic stimulation. Presented at the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA. *Neurology* 1996;46:A372-373.
 29. Hubble JP, **Lyons K**, Pahwa R, Koller WC (1997). Clinical features of Parkinson's disease: comparison of rural and urban residents. Presented at the International Parkinson's Disease Meeting, London, England. *Mov Disord* 1997;12(suppl 1):23.
 30. Hubble JP, Pahwa R, Sissel J, **Lyons K**, Koller WC (1997). Tremor in Parkinson's disease (PD). Presented at the 49th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 1997;48(suppl 2):A181.
 31. **Lyons KE**, Pahwa R, Koller WC (1997). Parkinson's disease symptoms and quality of life. Presented at the 49th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 1997;48(suppl 2):A181.
 32. **Lyons KE**, Troster AI, Pahwa R, Wilkinson S, Koller WC (1997). Post-Pallidotomy quality of life. Presented at the Eleventh Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's disease and on Hyperkinetic Movement Disorders, San Diego, CA. *Mov Disord* 1997;12:844.
 33. Miyawaki EK, **Lyons K**, Pahwa R, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC (1997). Complications of chronic L-dopa therapy. Presented at the 49th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 1997;48(suppl 2):A184.
 34. Pahwa R, Busenbark K, **Lyons K**, Wilkinson S, Hubble J, Koller WC (1997). Parkinson's disease tremor and thalamic deep brain stimulation. Presented at the 49th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 1997;48(suppl 2):A431.
 35. Pahwa R, **Lyons K**, Hubble JP, Riennerth J, Miyawaki K, Pahwa A, Koller WC. (1997). Double-blind placebo-controlled study of gabapentin in essential tremor. Presented at the 11th Annual symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and on Hyperkinetic Movement Disorders, San Diego, CA. *Mov Disord* 1997;12:836-837.
 36. Troster AI, Fields JA, Paolo AM, Pahwa R, **Lyons K**, Koller WC (1997). Relationship between ApoE-e4 and episodic memory in healthy elderly but not in Parkinson's disease. Presented at the 49th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 1997;48(suppl 2):A304.
 37. Baehr M, Pahwa R, **Lyons KE**, Wilkinson SB, Kieltyka J, Koller WC (1998). Incidence of seizures following stereotactic brain procedures. Presented at the 12th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease, Montreal, Canada. *Mov Disord* 1998;13:859.
 38. Fields JA, Tröster AI, Wilkinson SB, **Lyons KE**, Miyawaki E, Pahwa R, Koller WC. (1998). Comparison of the cognitive safety of unilateral pallidal stimulation and pallidotomy. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN. *Neurology* 1998;50(suppl 4):A389.

39. **Lyons KE**, Pahwa R, Wilkinson SB, Koller WC (1998). Long-term efficacy of globus pallidus stimulation for Parkinson's disease: 1 year follow-up. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN. *Neurology 1998;50(suppl 4):A79*.
40. **Lyons KE**, Troster AI, Pahwa R, DeCarli C, Koller WC (1998). Behavioral changes in Parkinson's disease patients with and without dementia. Presented at the 12th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease, Montreal, Canada. *Mov Disord 1998;13:861*.
41. Montgomery EB, Koller WC, **Lyons K** (1998). Preclinical detection of Parkinson's disease: a prospective study. Presented at the 5th International Congress of Parkinson's Disease and Movement Disorders, New York, NY. *Mov Disord 1998;13(suppl 2):39*.
42. Pahwa R, **Lyons K**, Ma MJ, Hubble JP, Handler M, Koller WC, DeCarli C (1998). Clinical diagnostic accuracy of Parkinson's disease: KU brain bank experience. Presented at the 5th International Congress of Parkinson's Disease and Movement Disorders, New York, NY. *Mov Disord 1998;13(suppl 2):249*.
43. Pahwa R, **Lyons KE**, Wilkinson SB, Koller WC (1998). Bilateral thalamic stimulation for essential tremor. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN. *Neurology 1998;50(suppl 4):A19*.
44. Smith T, **Lyons KE**, Pahwa R, Tröster AI, DeCarli C. (1998). Baseline and longitudinal changes in cognition among nondemented Parkinson's patients. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN. *Neurology 1998;50(suppl 4):A279*.
45. Straits-Tröster K, Fields JA, **Lyons KE**, Koller WC, Tröster AI. (1998). How do neurosurgical interventions for Parkinson's disease impact quality of life? Paper presented at the Annual Meeting of the Society of Behavioral Medicine, New Orleans, LA. *Ann Behav Med, 20 (Suppl), S117*.
46. Straits-Tröster K, Fields JA, Kieltyka J, **Lyons KE**, Koller WC, Tröster AI. (1998). Quality of life outcome following neurosurgical intervention for Parkinson's disease. Presented at the 26th Annual International Neuropsychological Society Conference, Honolulu, Hawaii. *J Intl Neuropsych Soc 1998; 4:37-38*.
47. Tröster AI, Fields JA, Straits-Tröster KA, **Lyons KE**, Miyawaki E, Wilkinson SB, Pahwa R, Kieltyka J, Koller WC. (1998). Motoric and psychosocial correlates of quality of life in Parkinson's disease four months after unilateral pallidotomy. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN. *Neurology 1998;50(suppl 4):A299*.
48. Troster AI, Fields JA, Piatt AL, **Lyons KE**, Wilkinson SB, Pahwa R, Koller WC. The role of the basal ganglia in lexical and semantic verbal fluency: clues from pallidotomy in Parkinson's disease. *Brain and Language 1998;65:115-117 (extended abstract)*.
49. Fields JA, Troster AI, Straits-Troster KA, Pahwa R, Wilkinson SB, **Lyons KE**, Koller WC. (1999). A comparison of neurobehavioral and quality of life outcomes in essential tremor following unilateral thalamic deep brain stimulation and thalamotomy. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology 1999;52(suppl 2):A519-520*.
50. Koller WC, Brin MF, Doucette J, **Lyons K**, Adler C, Comella C, Friedman J, Manyam B, Matsumoto J, Rajput A, Sethi K, Tanner C. (1999). Double blind assessment of Botulinum Toxin Type A (BOTOX) for essential hand tremor. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology 1999;52(suppl 2):A456*.
51. **Lyons KE**, Troster AI, Pahwa R, Wilkinson SB, Koller WC. (1999). The effect of deep brain stimulation of the thalamus and globus pallidus on quality of life in Parkinson's disease. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology 1999;52(suppl 2):A404*.
52. Pahwa R, **Lyons KE**, Troster AI, Wilkinson SB, Koller WC (1999). Comparison of thalamotomy to deep brain stimulation (DBS) of the thalamus in essential tremor (ET). Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology 1999;52(suppl 2):A457*.

53. Pahwa R, **Lyons K**, Wilkinson S, Baehr M, Troster A, Overman J, Koller W (1999). Bilateral subthalamic (STN) stimulation in Parkinson's disease (PD) patients with previous stereotactic surgeries. Presented at the 13th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, Seattle, WA. *Mov Disord* 1999;14:899.
54. Santa Cruz K, Pahwa R, **Lyons K**, Troster A, Handler M, Koller W, DeCarli C (1999). Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology* 1999;52(suppl 2):A476-477.
55. Smith T, Pahwa R, **Lyons K**, Troster A, Koller W, DeCarli C (1999). Longitudinal differences in cognitive performance in demented versus non-demented Parkinson's disease patients. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology* 1999;52(suppl 2):A485-486.
56. Troster AI, Fields JA, Pahwa R, Wilkinson SB, Straits-Troster KA, **Lyons KE**, Koller WC (1999). Cognitive functioning, mood state, and quality of life after unilateral thalamic deep brain stimulation for essential tremor. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. *Neurology* 1999;52(suppl 2):A457.
57. Troster AI, Straits-Troster KA, Fields JA, **Lyons KE**, Pawha R, Koller WC (1999). Disease-specific quality of life correlates before pallidotomy. Presented at the 13th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, Seattle, WA. *Mov Disord* 1999;14:905.
58. Troster A, Fields J, **Lyons K**, Wilkinson S, Koller W (1999). Neurobehavioral and quality of life outcome after left and right pallidotomy. Presented at the 2nd International Congress on Mental Dysfunction and Parkinson's Disease, Amsterdam, The Netherlands. *Park Rel Disord* 1999;5(Suppl 2):42.
59. Fukuda M, Mentis M, Dhawan V, **Lyons K**, Koller WC, Eidelberg D (2000). Metabolic correlates of clinical outcome with pallidal deep brain stimulation for Parkinson's disease. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, California. *Neurology* 2000;54(suppl 3):A283.
60. Koller WC, **Lyons KE**, Wilkinson SB, Troster AI, Pahwa R. (2000). Long-term follow-up of deep brain stimulation (DBS) of the thalamus for the treatment of essential tremor (ET). Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, California. *Neurology* 2000;54(suppl 3):A237-238.
61. Pahwa R, **Lyons KE**, Wilkinson SB, Troster AI, Baehr M, Koller WC. (2000). Safety and efficacy of bilateral subthalamic stimulation in Parkinson's disease. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, California. *Neurology* 2000;54(suppl 3):A477.
62. Pahwa R, **Lyons K**, Wilkinson S, Koller W. (2000). Long-term use of unilateral thalamic stimulation for Parkinson's disease. 6th International Congress of Parkinson's Disease and Movement Disorders, Barcelona, Spain. *Mov Disord* 2000;15(suppl 3):45.
63. Pahwa R, **Lyons KE**, Overman J, Wilkinson SB, Koller WC. (2000). Safety and efficacy of thalamic stimulation with and without microelectrode recording. Presented at the 14th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, Boston, MA. *Mov Disord* 2000;15:1039.
64. Straits-Troster KA, Troster AI, Fields JA, **Lyons K**, Koller WC. (2000) Determinants of quality of life following thalamic stimulation for essential tremor. Presented at the International Neuropsychological Society Mid-Year Conference, Brussels, Belgium. *J Intl Neuropsych Soc* 2000;6:413.
65. Tanner CM, Koller WC, Goldman SM, **Lyons KE**, Aston DA, Tetud JW, Welsh MD, Langston JW. (2000) Shared determinants of essential tremor (ET) and Parkinson's disease (PD): A study in twins. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, California.

- Neurology* 2000;54(suppl 3):A237.
66. Troster AI, Fields JA, Straits-Troster KA, **Lyons KE**, Higginson CI, Chmidling S, Pahwa R, Koller WC (2000) Executive function, coping, mood state, and quality of life in Parkinson's disease patients being evaluated for pallidotomy. Presented at the Annual Meeting of the International Neuropsychological Society, Denver, Colorado. *J Intl Neuropsych Soc* 2000;6:207.
 67. **Lyons KE**, Koller WC, Wilkinson SB, Pahwa R. (2001). Surgical and device-related events with deep brain stimulation. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pennsylvania. *Neurology* 2001;56(suppl 3):A147.
 68. **Lyons KE**, Koller WC, Wilkinson SB, Pahwa R. (2001) Thalamic stimulation for rubral tremor: a case report. Presented at the 14th International Congress on Parkinson's Disease, Helsinki, Finland. *Parkinsonism and Related Disorders* 2001;7(suppl):S81.
 69. Pahwa R, **Lyons KE**, Wilkinson SB, Koller WC. (2001). One year follow-up of bilateral subthalamic stimulation in Parkinson's disease. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pennsylvania *Neurology* 2001;56(suppl 3):A146.
 70. Pahwa R, **Lyons KE**, Wilkinson SB, Koller WC. (2001). Does patient age affect outcome of deep brain stimulation of the subthalamic nucleus in Parkinson's disease? Presented at the 14th International Congress on Parkinson's Disease, Helsinki, Finland. *Parkinsonism and Related Disorders* 2001;7(suppl):S83.
 71. Troster AI, Fields JA, **Lyons K**, Straits-Troster KA, Wilkinson SB, Pahwa R, Koller WC (2001). Predictors and correlates of quality of life improvements after subthalamic deep brain stimulation in Parkinson's disease. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pennsylvania. *Neurology* 2001;56(suppl 3):A277.
 72. Pahwa R, **Lyons KE**, Troster AI, Koller WC, Wilkinson S. (2001). Long-term open label evaluation of globus pallidus stimulation for the treatment of Parkinson's disease. Presented at the 15th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, Chicago, Illinois *Mov Disord* 2001;16:2.
 73. Fields JA, Woods SP, **Lyons KE**, Pahwa R, Koller WC, Troster AI. (2002). Frequency of thalamic deep brain stimulation is related to verbal fluency declines in essential tremor. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado. *Neurology* 2002;58(suppl 3):A220.
 74. **Lyons KE**, Greene MS, Pahwa R. (2002). Use of acupuncture in Parkinson's disease: a pilot study. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado. *Neurology* 2002;58(suppl 3):A466.
 75. **Lyons KE**, Pahwa R. (2002). A double-blind, placebo-controlled, pilot study of mirtazapine in essential tremor. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado. *Neurology* 2002;58(suppl 3):A254.
 76. Pahwa R, Dascalos S, Overman J, **Lyons KE**. (2002). Programming time for bilateral subthalamic stimulators in Parkinson's disease. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado. *Neurology* 2002;58(suppl 3):A55.
 77. Pahwa R, Wilkinson SB, Koller WC, **Lyons KE**. (2002). Bilateral subthalamic nucleus stimulation in Parkinson's disease: a long-term follow-up. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado. *Neurology* 2002;58(suppl 3):A61.
 78. Singer C, Uzcategui G, **Lyons K**, Facca A, Koller W. (2002). Efficacy and tolerability of amantadine: a retrospective review of old and new indications at a tertiary referral center. Presented at the 7th International Congress of Parkinson's Disease and Movement Disorders. Miami, Florida. *Mov Disord* 2002;17(suppl 5):S97.
 79. Vela L, Facca A, **Lyons KE**, Lieberman AN. (2002). Pain and Parkinson's disease. Presented at the 7th International Congress of Parkinson's Disease and Movement Disorders. Miami, Florida. *Mov Disord* 2002;17(suppl 5):S154-155.

80. Rakocevic G, **Lyons KE**, Wilkinson SB, Kieltyka J, Pahwa R. (2002). Bilateral pallidotomy for severe dystonia in a child with Glutaric Aciduria: a case report. Presented at the 7th International Congress of Parkinson's Disease and Movement Disorders. Miami, Florida. *Mov Disord* 2002;17(suppl 5):S186.
81. Tröster AI, Fields JA, Wilkinson S, Pahwa R, **Lyons KE**, Koller W. (2003). Motor improvement's effect on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. Presented at the Quadrennial Meeting of the American Society for Stereotactic and Functional Neurosurgery, New York, NY.
82. **Lyons KE**, Wilkinson SB, Troster AI, Pahwa R. (2003). Long-term benefits in quality of life after bilateral subthalamic stimulation for Parkinson's disease. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003;60(suppl 1):A122.
83. **Lyons KE**, Wilkinson SB, Pahwa R. (2003). A 9-year follow-up review of essential tremor patients who underwent deep brain stimulation of the thalamus. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003;60(suppl 1):A123.
84. Pahwa R, Wilkinson SB, Overman J, **Lyons KE**. (2003). Preoperative predictors of response to bilateral subthalamic stimulation in patients with Parkinson's disease. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003;60(suppl 1):A163.
85. Pahwa R, **Lyons KE**, Jankovic J, Tarsy D, Hauser R and the Thalamic Stimulation Study Group. (2003). Five-year safety and efficacy of thalamic deep brain stimulation in Parkinson's disease and essential tremor: a multicenter study. Presented at the 17th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. San Francisco, California. *Mov Disord* 2003;18:1086-1087.
86. **Lyons KE**, Lambrecht K, Esnaashari F, Pahwa R. (2003). The use of an electronic diary for patients with Parkinson's disease: a pilot study. Presented at the 17th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. San Francisco, California. *Mov Disord* 2003;18:1092.
87. **Lyons KE**, Wilkinson SB, Overman J, Pahwa R. (2004). Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, California. *Neurology* 2004;62(suppl 5):A392.
88. **Lyons KE**, Wilkinson SB, Pahwa R. (2004). The effects of bilateral subthalamic nucleus stimulation on sleep symptoms and early morning dystonia in Parkinson's disease. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, California. *Neurology* 2004;62(suppl 5):A106.
89. **Lyons KE**, Wilkinson SB, Pahwa R. (2004). Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa therapy. Presented at the 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy. *Mov Disord* 2004;19(Suppl 9):S282.
90. **Lyons KE**, Wilkinson SB, Pahwa R. (2004) Freezing after bilateral subthalamic nucleus stimulation for Parkinson's disease. Presented at the 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, Toronto, Canada. *Mov Disord* 2004;19:1129.
91. Pahwa R, **Lyons KE**. (2004). Depression and quality of life in essential tremor patients. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, California. *Neurology* 2004;62(suppl 5):A502.
92. Ross GW, Dickson D, Cersosimo M, Tsuboi Y, Katsuse O, Petrovitch H, Hardman J, **Lyons K**, Koller W. (2004). Pathological investigation of essential tremor. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, California. *Neurology* 2004;62(suppl 5):A537-538.
93. Tintner R for the Tremor Research Group. The tremor rating scale (TRS). Presented at the 18th Annual

- Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, Toronto, Canada. *Mov Disord* 2004;19:1131-1132.
94. Troster AI, Pahwa R, Fields JA, Tanner CM, **Lyons KE**. (2004) Development of the quality of life in essential tremor questionnaire (QUEST): a 30-item disease-specific quality of life instrument. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, California. *Neurology* 2004;62(suppl 5):A500-501.
 95. Troster AI, Pahwa R, Tanner CM, **Lyons KE**. (2004). Validation of the Quality of Life in Essential Tremor questionnaire (QUEST). Presented at the 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy. *Mov Disord* 2004;19(Suppl 9):S405.
 96. Vela L, **Lyons KE**, Singer C, Lieberman AN. (2004). Pain-pressure threshold in patients with Parkinson's disease with and without dyskinesia. Presented at the 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy. *Mov Disord* 2004;19(Suppl 9):S168.
 97. LeWitt PA, Jennings D, **Lyons KE**, Pahwa R, Rabinowicz AL, Guarnieri M, Hubble, J. (2005) Pharmacokinetics and pharmacodynamic comparison of Sinemet® CR 50/200 and Stalevo® 150 in Parkinson's disease: A 2 x 2 crossover study. Presented at the 32nd Annual Meeting of the Southern Clinical Neurology Society (SCNS), Huatulca, Mexico.
 98. Pahwa R, **Lyons KE**. (2005) Conversion from sustained release carbidopa/levodopa to Stalevo® in Parkinson's disease patients. Presented at the 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA. *Mov Disord* 2005;20(Suppl 10):S71.
 99. Eng M, **Lyons K**, Pahwa R. (2005) A survey of coenzyme Q10 use in Parkinson's disease clinic outpatients. Presented at the 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA. *Mov Disord* 2005;20(Suppl 10):S78
 100. **Lyons KE**, Wilkinson SB, Pahwa R. (2005) Are mild MRI abnormalities predictive of outcome after bilateral subthalamic stimulation for Parkinson's disease? Presented at the 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA. *Mov Disord* 2005;20(Suppl 10):S150.
 101. LeWitt P, Jennings D, **Lyons K**, Pahwa R, Rabinowicz A, Guarnieri M, Hubble J. (2005). Pharmacokinetic and pharmacodynamic comparison of Sinemet CR 50/200 and Stalevo 150 in Parkinson's disease: A 2x2 crossover. Presented at the 57th Annual American Academy of Neurology, Miami, Florida *Neurology* 2005;64(suppl 1):A106-A107.
 102. **Lyons KE**, Troster AI, Tanner CM, Pahwa R. (2005). QUEST: A disease specific measure of quality of life in essential tremor patients. Presented at the 57th Annual American Academy of Neurology, Miami, Florida *Neurology* 2005;64(Suppl 1):A254-A255.
 103. Kleiner-Fisman G, Herzog J, Deuschl G, Lang AE, **Lyons K**, Pahwa R, Tamma F, Fisman D. (2005). Subthalamic nucleus deep brain stimulation: a meta-analysis of outcomes. Presented at the 19th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, California *Mov Disord* 2005;20:1237.
 104. Parkinson Study Group. (2005) A randomized controlled trial of etilevodopa in Parkinson's disease patients with motor fluctuations. Presented at the 19th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, California *Mov Disord* 2005;20:1237.
 105. Louis ED, Vonsattel JPG, Hong LS, Ross GW, **Lyons KE**, Pahwa R. (2005). Essential tremor pathology : a case control study from the Essential Tremor Centralized Brain Repository. Presented at the 19th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, California *Mov Disord* 2005;20:1241.
 106. Pahwa R, Wilkinson SB, **Lyons KE**. (2005). Unilateral cortical stimulation in essential tremor. Presented at the 19th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, California *Mov Disord* 2005;20:1246-1247.
 107. Pahwa R, **Lyons K**, Hamburg J, Clair AA. (2006). The effects of the "Motivating Moves for People

- with Parkinson's" exercise program on the participants' physical function and quality of life. Presented at the 1st World Parkinson Congress, Washington, DC. *Mov Disord* 2006;21(suppl 13):S141.
108. Verhagen Metman L, Pahwa R, **Lyons K**, Sherman S, Bakay R, Wilkinson S, Weinand M. (2006). Motor cortex stimulation in Parkinson's disease: a pilot study. Presented at the 58th Annual Meeting of the American Academy of Neurology, San Diego, California. *Neurology* 2006;66(suppl 5):A47.
 109. Watts RL, Pahwa R, **Lyons KE**, Boroojerdi B (2006). Long-term safety and efficacy of the rotigotine transdermal patch in early-stage Parkinson's disease. Presented at the 10th International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan. *Mov Disord* 2006;21(suppl 15):S606.
 110. Pankratz N, Halter C, Rudolph A, Shults C, Nichols W, Foroud T and the Parkinson Study Group – PROGENI Investigators. Depression in a cohort of 1335 individuals with familial Parkinson disease. Presented at the 59th Annual Meeting of the American Academy of Neurology, Boston, MA. *Neurology* 2007;68(suppl 1):A37.
 111. LeWitt PA, **Lyons KE**, Pahwa R. Rotigotine transdermal patch as adjunct to levodopa in the treatment of advanced-stage Parkinson's patients. Presented at the 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey. *Mov Disord* 2007;22(suppl 16):S177.
 112. Louis ED, Axelrad JE, Honig LS, Flores I, Ross GW, Pahwa R, **Lyons KE**, Faust PL, Vonsattel JPG. Reduced purkinje cell number in essential tremor: a postmortem study. Presented at the 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey. *Mov Disord* 2007;22(suppl 16):S293.
 113. Vela L, **Lyons KE**, Pareja JA, Dobato JL, Barriga FJ, Sanchez C, Baron M, Polo AP, Borrega L. Prevalence of non-motor symptoms in Parkinson's disease symptoms. Presented at the 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey. *Mov Disord* 2007;22(suppl 16):S293.
 114. Watts RL, Pahwa R, **Lyons KE**, Boroojerdi B. Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease. Presented at the 21st Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, Washington, DC. *Mov Disord* 2007;22:XIV.
 115. Stylianou AP, McVey MA, Luchies CW, **Lyons KE**, Pahwa R. Altered response to a backwards pull in Parkinson's disease. Presented at the American Society of Biomechanics Annual Meeting, Palo Alto, California, 2007.
 116. McVey MA, Stylianou AP, Luchies CW, **Lyons KE**, Pahwa R, Jernigan S. Effect of Parkinson's disease on step response to a backwards pull. Presented at the American Society of Biomechanics Annual Conference. Palo Alto, California, 2007.
 117. Isaacson SH, Pahwa R, **Lyons KE**, Brunson G, Porter M and the A to Z Study Group. Design of the A to Z (Agonist to Zelapar) trial: adding orally disintegrating selegiline to dopamine agonists in patients with Parkinson's disease experiencing complications. Presented at the 17th WFN World Congress on Parkinson's Disease and Related Disorders, Amsterdam, The Netherlands. *Parkinsonism Relat Disord* 2007;13(suppl 2):S98.
 118. **Lyons KE**, Pahwa R, Boroojerdi B. Evaluation of open-label rotigotine treatment in advanced Parkinson's disease. Presented at the 60th Annual Meeting of the Academy of Neurology, Chicago, IL. *Neurology* 2008;70(suppl 1):A59.
 119. Louis ED, Faust PL, Vonsattel JPG, Honig LS, Rajput A, Robinson CA, Rajput A, Pahwa R, **Lyons K**, Ross W. Neuropathological changes in essential tremor: a postmortem study of 33 cases compared with 21 controls. Presented at the 60th Annual Meeting of the Academy of Neurology, Chicago, IL. *Neurology* 2008;70(suppl 1):A120.
 120. Nazzaro JM, **Lyons K**, Ridings LW, Haynes NG, Grant JA, Pahwa R. Variability in microelectrode length. Presented at the Annual Meeting of the American Association of

- Neurological Surgeons, Chicago, IL. *J Neurosurg* 2008;108:A905.
121. Kemper S, McDowd J, Burns J, Pahwa R, **Lyons K**. The effects of aging and neurological disease on two components of verbal fluency. Presented at the Cognitive Aging Conference 2008, Atlanta, Georgia, 2008.
 122. McVey M, Stylianou A, Luchies C, **Lyons K**, Pahwa R, Jernigan S, Mahnken J. The effect of Parkinson's disease on the step response to a backwards pull. Presented at the 2008 Summer Bioengineering Conference, Marco Island, Florida, 2008.
 123. Onyszchuk G, **Lyons KE**, Pahwa R, Nazzaro JM. Considerations regarding heating of deep brain stimulation leads during 3.0T magnetic resonance imaging. Presented at the American Society for Stereotactic and Functional Neurosurgery, Vancouver, BC, 2008.
 124. Nazzaro JM, Haynes NG, **Lyons KE**, Pahwa R. Head positioning during DBS surgery. Presented at the American Society for Stereotactic and Functional Neurosurgery, Vancouver, BC, 2008.
 125. Haynes NG, Johnson PL, **Lyons KE**, Pahwa R, Nazzaro JM. DBS lead placement in the setting of ventriculomegaly, signal artifact and anatomic distortions. Presented at the American Society for Stereotactic and Functional Neurosurgery, Vancouver, BC, 2008.
 126. Nazzaro JM, **Lyons KE**, Pahwa R. Kansas experience with brain MRI after DBS hardware implantation. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(suppl 1):S62-S63.
 127. Searl J, Haring K, Pahwa R, **Lyons KE**. Telemedicine versus face-to-face group voice therapy for persons with Parkinson's disease. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S202-S203.
 128. Pahwa R, **Lyons KE**, A to Z Study Investigators. The addition of orally disintegrating selegiline in Parkinson's disease patients experiencing dopamine agonist related adverse events: The A to Z Study. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S210.
 129. **Lyons KE**, Pahwa R, Boroojerdi B. Evaluation of open-label rotigotine treatment in advanced Parkinson's disease. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1): S215.
 130. Ray A, Eng M, **Lyons KE**, Pahwa R. An open label pilot study of transdermal selegiline for depression in Parkinson's disease patients. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S304-S305.
 131. Pahwa R, **Lyons KE**. An open-label conversion study of pramipexole to ropinirole prolonged release in patients with Parkinson's disease. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S314.
 132. Hamburg J, Clair A, **Lyons KE**. Improvements in daily functioning and walking ability with Motivating Moves for People with Parkinson's exercise program: a pilot study. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S338.
 133. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos J, Louis E, **Lyons K**, Ondo W, Pahwa R, Sethi K, Stern M, Tanner C, Tarsy D, Tintner R, Watts R, Tremor Research Group. The essential tremor rating assessment scale (TETRAS). Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S357.
 134. Louis ED, Faust PL, Vonsattel JPG, Honig LS, Henchcliffe C, Pahwa R, **Lyons KE**. Older onset essential tremor is associated with more rapid progression and more degenerative pathology. Presented at the 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois, 2008. *Mov Disord* 2008;23(Suppl 1):S389.
 135. **Lyons KE**, Pahwa R, Boroojerdi B. Evaluation of open-label rotigotine treatment in advanced Parkinson's disease. Presented at the 12th Congress of the European Federation of Neurological Societies, Madrid, Spain, 2008. *Eur J Neurol* 2008;15 (Suppl 3):118.

136. Pahwa R, **Lyons KE**. A three-arm, open-label conversion study of pamipexole to ropinirole prolonged release tablets in Parkinson's disease patients. Presented at the 12th Congress of the European Federation of Neurological Societies, Madrid, Spain, 2008. *Eur J Neurol* 2008;15 (Suppl 3):126-127.
137. LeWitt PA, **Lyons KE**, Pahwa R, Poewe W, Rascol O, Quinn N, Tolosa E, Oertel WM, Boroojerdi B. Safety and tolerability of rotigotine in advanced Parkinson's disease. Presented at the 133rd Meeting of the American Neurological Association, Salt Lake City, Utah, 2008. *Ann Neurol* 2008; 64 (suppl 12):S54-S55.
138. McVey MA, Stylianou AP, Luchies CW, Haines M, **Lyons KE**, Pahwa R. The effect of Parkinson's disease on the response to a backwards pull: center of pressure. Presented at the North American Congress on Biomechanics, Ann Arbor, Michigan, 2008.
139. Muniz AMS, Nobre FF, Liu H, **Lyons KE**, Pahwa R, Liu W, Nadal J. Assessment of the effects of subthalamic stimulation in Parkinson disease patients by artificial neural network. Presented at the 30th Annual International IEE EMBS Conference, Vancouver, British Columbia, Canada, 2008.
140. Louis ED, Faust P, Vonsattel JP, Honig L, Rajput A, Rajput A, Pahwa R, **Lyons K**, Ross W, Elble R, Erickson-Davis C. Torpedoes in essential tremor, Parkinson's disease, Alzheimer's disease, and control brains. Presented at the 61st Annual Meeting of the American Academy of Neurology, Seattle, Washington. *Neurology* 2009;72(suppl 3):A101.
141. Stylianou A, Luchies C, McVey M, **Lyons K**, Pahwa R. Postural sway changes in mild to moderate Parkinson's disease. Presented at the American Society of Biomechanics, University Park, PA, 2009.
142. McVey M, Stylianou A, **Lyons K**, Pahwa R, Luchies C, Cheney P. Comparison of an automatic and voluntary task in early Parkinson's disease. Presented at the American Society of Biomechanics, University Park, PA, 2009.
143. Watts R, Pahwa R, **Lyons K**, Boroojerdi B. Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: Results from 4 years. Presented at the 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, 2009. *Mov Disord* 2009;24(suppl 1):S286.
144. Pahwa R, Poewe W, **Lyons K**, Boroojerdi B. Changes in early morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD). Presented at the 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, 2009. *Mov Disord* 2009;24(suppl 1):S280.
145. Watts RL, Giorgi L, Rolfe K, **Lyons KE**. Adjunctive ropinirole prolonged-release has similar effects on motor and non-motor symptoms in PD compared with carbidopa-levodopa, but delays dyskinesia onset. Presented at the WFN XVIII World Congress of Parkinson's Disease and Related Disorders, Miami Beach, Florida, 2009. *Parkinsonism Relat Disord* 2009;15(suppl 2):S137.
146. Pahwa R, Poewe W, **Lyons K**, Boroojerdi B. Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials. Presented at the WFN XVIII World Congress of Parkinson's Disease and Related Disorders, Miami Beach, Florida, 2009. *Parkinsonism Relat Disord* 2009;15(suppl 2):S130-131.
147. Watts R, Pahwa R, **Lyons K**, Boroojerdi B. Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: four year results. Presented at the WFN XVIII World Congress of Parkinson's Disease and Related Disorders, Miami Beach, Florida, 2009. *Parkinsonism Relat Disord* 2009;15(suppl 2):S137.
148. Hanna-Pladdy B, Enslein A, Fray M, Gajewski, Pahwa R, **Lyons KE**. Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: Comparison to the MMSE and MoCA. Presented at the 24th Annual Symposium of Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, Irving, Texas, 2010. *Mov Disord* 2010;25:V.
149. Schulz G, Bradberry TJ, Hosey LA, Stager S, Li-Ching L, Pahwa R, **Lyons K**, Verhagen L, Braun A.

Dissociated effects of left, right and bilateral stimulation of the subthalamic nucleus on motor, speech and language function in Parkinson's disease. Presented at the 2nd World Parkinson Congress, Glasgow, Scotland, 2010. *Mov Disord* 2010;25(Suppl 3):S671-672.

150. Troster AI, **Lyons K**, Pahwa R, Fields JA. Preoperative mild cognitive impairment (MCI) and cognitive outcome after subthalamic deep brain stimulation for Parkinson's disease. Presented at the 63rd Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii, 2011. *Neurology* 2011;76(Supplement 4):A39.
151. Chu S, Barlow SM, Lee J, Pahwa R, **Lyons K**. (2011). Perioral biomechanics, kinematics, and electrophysiology in Parkinson's disease. Presented at the 6th International Speech Motor Conference, Groningen-Nijmegen, The Netherlands, June 9-11.